The preferential overexpression of B7H3 protein on the surface of cancer cells and the minimal expression on normal tissues makes it an ideal target for antibody-based therapeutics (11, 12), and targeting B7H3 is being widely pursued as more than 30 clinical trials are currently registered on clinicaltrials.gov. Here, CD276 is linked to cancer.